Memantine is a non-acetyl cholinesterase inhibitor drug that aids in treatment of Alzheimer's disease. The drug received European marketing approval in 2002 and the U.S. Food and Drug Administration (U.S FDA) approval in 2003. The generic versions of the drugs are available since 2015. Memantine aids in treatment of moderate to severe dementia associated with Alzheimer's disease. However the drug may show a severe skin reaction called Stevens-Johnson syndrome (associated with painful blisters on the skin) after prolonged use.
Memantine Market– Drivers
Increasing number of pipeline studies for use of memantine are expected to boost growth of the memantine market. For instance, in September 2016, Lille University Hospital started phase I clinical study for assessing the effects of memantine on cognitive behavior of patients associated with Alzheimer’s disease. The study is estimated to be completed by February 2019.
Furthermore, Suven Life Sciences Limited is undergoing phase II clinical study for the comparative study on safety and efficacy of SUVN-502 along with memantine HCl and donezepil HCl for treating moderate Alzheimer’s disease. The study was started in September 2015 and is expected to be completed in May 2019.
Memantine Market– Restraint
Increasing number of expired patents of drugs is a major factor hindering growth of the global memantine market. For instance, according Merz Pharmaceuticals, a Germany-based company, in October 2018, overall licensing income during patented period for memantine decreased due to expiration of patent protection in a majority of markets. For instance, according to Merz Pharmaceuticals, the U.S. licensing income for memantine declined to US$ 138.07 million in 2017-18 compared to US$ 183.34 million in year 2016.
Memantine Market– Regional Analysis
On the basis of region, the global memantine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global memantine market, owing to increasing number of generic versions of memantine in the U.S. market. For instance, in February 2018, Lupin Limited announced the launch of its Memantine Hydrochloride Extended-Release Capsules in the U.S. market. The capsules are available in 7mg, 14mg, 21mg, and 28mg, for which company has received an approval from the U.S. FDA. These are indicated for the treatment of moderate to severe dementia of the Alzheimer’s disease.
Furthermore, Asia Pacific is expected to witness significant growth in the global memantine market, owing to increasing focus of key players in manufacturing memantine tablets. For instance, in October 2018, Dr. Reddy’s Laboratories launched memantine hydrochloride tablets in the Indian market. They are available in 5mg and 10mg, equivalent to generic version of Namenda tablets, which were already available in the U.S. market in July 2015.
Memantine Market– Competitive Analysis
Key players operating in the global memantine market include, Merz Pharmaceuticals, Lupin Limited, Allergan plc. Novartis AG, Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co Ltd., Eisai Co., Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories, and Johnson & Johnson Services, Inc.
Memantine Market– Taxonomy
By Distribution Channel
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.